Last reviewed · How we verify

MINIRIN Oral Lyophilisate

Ferring Pharmaceuticals · FDA-approved active Small molecule Quality 5/100

MINIRIN Oral Lyophilisate is a Small molecule drug developed by Ferring Pharmaceuticals. It is currently FDA-approved.

MINIRIN Oral Lyophilisate, marketed by Ferring Pharmaceuticals, is an established product with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging Ferring's strong commercial infrastructure. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameMINIRIN Oral Lyophilisate
SponsorFerring Pharmaceuticals
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MINIRIN Oral Lyophilisate

What is MINIRIN Oral Lyophilisate?

MINIRIN Oral Lyophilisate is a Small molecule drug developed by Ferring Pharmaceuticals.

Who makes MINIRIN Oral Lyophilisate?

MINIRIN Oral Lyophilisate is developed and marketed by Ferring Pharmaceuticals (see full Ferring Pharmaceuticals pipeline at /company/ferring).

What development phase is MINIRIN Oral Lyophilisate in?

MINIRIN Oral Lyophilisate is FDA-approved (marketed).

Related